文献速递淋巴瘤造血干细胞移植与细胞治疗

弥漫大B细胞淋巴瘤患者接受自体干细胞移植中(18)F-氟脱氧葡萄糖正电子发射断层显像的预后意义

[Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

该回顾性分析纳入2010年11月至2014年12月在北京大学肿瘤医院接受auto-HSCT的48例DLBCL患者,评估移植前、后PET/CT的预后价值。移植后PET/CT评估阳性是PFS(HR=13.176,P=0.005)和OS(HR=20.221,P=0.007)的预后不良因素;移植后PET/CT评估联合移植前治疗方案数及ECOG体力状态评分可提高预测价值。

要点

  • 移植前PET/CT阴性者3年PFS 87.1% vs 阳性者53.3%(P=0.019),3年OS 90.3% vs 60.0%(P=0.022)。
  • 移植后PET/CT阴性者3年PFS 94.1% vs 阳性者30.0%(P=0.001),3年OS 97.1% vs 40.0%(P=0.002)。
  • 移植后PET/CT评估阳性是PFS(HR=13.176)和OS(HR=20.221)的预后不良因素。

核心结论

  • 移植后PET-CT评估在接受auto-HSCT的DLBCL患者中有重要预后作用。
  • 移植后PET-CT评估联合移植前治疗方案数以及ECOG体力状态评分可能能够更好地预测患者预后。

研究设计与样本

  • 回顾性分析2010年11月至2014年12月在北京大学肿瘤医院接受auto-HSCT的48例DLBCL患者资料。

主要发现

  • 48例患者中男27例、女21例,中位年龄43(17~59)岁。
  • 移植前PET-CT评估阴性与阳性患者的3年PFS率分别为87.1%和53.3%(χ²=7.02,P=0.019),3年OS率分别为90.3%和60.0%(χ²=6.51,P=0.022)。
  • 移植后PET-CT评估阴性与阳性患者的3年PFS率分别为94.1%和30.0%(χ²=22.75,P=0.001),3年OS率分别为97.1%和40.0%(χ²=21.09,P=0.002)。
  • 多因素分析显示移植后PET-CT评估阳性是影响PFS(HR=13.176,P=0.005)和OS(HR=20.221,P=0.007)的预后不良因素,移植前治疗方案数与PFS相关(HR=10.039,P=0.040)。
  • Harrell's C值显示联合使用预测PFS的Harrell's C值为0.976,优于移植前治疗方案数的0.869和移植后PET-CT评估的0.927;联合使用预测OS的Harrell's C值为0.973,优于ECOG体力状态评分的0.711和移植后PET-CT评估的0.919。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the prognostic value of (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) in patients with diffuse large B cell lymphoma (DLBCL) undergoing autologous hematopoietic stem cell transplantation (auto-HSCT). Methods: Forty-eight patients with DLBCL treated at Peking University Cancer Hospital between November 2010 and December 2014 were assessed. All patients underwent PET/CT scanning prior to or after auto-HSCT. Correlation analysis was done based upon patients characteristics, PET/CT scan results and survival. Results: ①Among 48 patients, 27 was male, 21 female, median age was 43 (17-59) years old. ② Patients with negative pre-auto-HSCT PET/CT assessment demonstrated significantly better 3-year progression free survival (PFS) (87.1% vs 53.3%, χ(2)=7.02, P=0.019) and overall survival (OS) (90.3% vs 60.0%, χ(2)=6.51,P=0.022) than patients with positive pre-auto-HSCT PET/CT assessment. Three-year PFS (94.1% vs 30.0%, χ(2)=22.75, P=0.001) and OS (97.1% vs 40.0%, χ(2)=21.09, P=0.002) were also significantly different between patients with negative and positive post-auto-HSCT PET/CT assessment. ③ Multivariate analysis indicated a significant association of PFS (HR=13.176, P=0.005) and OS (HR=20.221, P=0.007) with post-auto-HSCT PET/CT assessment. Number of prior treatment regimens was associated with PFS (HR=10.039, P=0.040). ④ Harrell's C index revealed that the value of combined use of number of prior treatment regimens and post-auto-HSCT PET/CT assessment was superior to either one used alone in PFS (Harrell's C values were 0.976, 0.869 and 0.927 in combined use, number of prior treatment regimens and post-auto-HSCT PET/CT assessment, respectively), and the combined use of ECOG performance status and post-auto-HSCT PET/CT assessment significantly increased the Harrell's C index in OS (Harrell's C values were 0.973, 0.711 and 0.919 in combined use, ECOG performance status and post-auto-HSCT PET/CT assessment, respectively). Conclusions: Post-auto-HSCT PET/CT assessment is the main predictor of outcomes in DLBCL patients receiving auto-HSCT. Combined use of post-auto-HSCT PET/CT assessment and number of prior treatment regimens and ECOG performance status is a better prognostic tool in patients with DLBCL undergoing transplantation. 目的: 探讨(18)F-FDG PET-CT评估在接受auto-HSCT的弥漫大B细胞淋巴瘤(DLBCL)患者中的预后价值。 方法: 回顾性分析2010年11月至2014年12月在北京大学肿瘤医院接受auto-HSCT的48例DLBCL患者资料,所有患者移植前或者移植后行PET-CT检查,结合患者基本临床特征及生存进行相关性分析。 结果: ①48例患者中,男27例,女21例,中位年龄为43(17~59)岁。②移植前PET-CT评估阴性和阳性患者的3年无进展生存(PFS)率分别为87.1%和53.3%(χ(2)=7.02,P=0.019),3年总生存(OS)率分别为90.3%和60.0%(χ(2)=6.51,P=0.022);移植后两组患者的3年PFS率分别为94.1%和30.0%(χ(2)=22.75,P=0.001),3年OS率分别为97.1%和40.0%(χ(2)=21.09,P=0.002)。③多因素分析结果显示,移植后PET-CT评估阳性是影响患者PFS(HR=13.176,P=0.005)和OS(HR=20.221,P=0.007)的预后不良因素;移植前治疗方案数与PFS相关(HR=10.039,P=0.040)。④Harrell’s C值显示移植后PET-CT评估与移植前治疗方案数联合使用预测PFS的价值优于单独使用(联合使用、移植前治疗方案数、移植后PET-CT评估的Harrell’s C值分别为0.976、0.869、0.927);移植后PET-CT与ECOG体力状态评分联合使用能更好预测OS(联合使用、ECOG体力状态评分、移植后PET-CT评估的Harrell’s C值分别为0.973、0.711、0.919)。 结论: 移植后PET-CT评估在接受auto-HSCT的DLBCL患者中有重要预后作用,移植后PET-CT评估联合移植前治疗方案数以及ECOG体力状态评分可能能够更好地预测患者预后。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ying ZT, Mi L, Wang XJ, et al. [Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29779346. doi:10.3760/cma.j.issn.0253-2727.2018.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。